Global edition
Market data — delayed ~15 min · Last updated: November 16, 2026, 7:44 pm CST
S&P 5007,416.59-1.92%Nasdaq 10027,197.15-2.67%Dow Jones51,608.17-1.41%Shanghai Comp3,634.35-0.59%Nikkei 22559,078.52-3.38%FTSE 10010,902.60+0.36%DAX26,749.95-0.08%CAC 408,368.91+0.09%Hang Seng23,637.60-1.55%ASX 2008,906.20-1.94%Sensex81,592.45-0.39%
← Back to briefing Global edition · Corporate America
Corporate America

Johnson & Johnson to Acquire Ollin Biosciences in Deal Worth Up to $3.33 Billion

Johnson & Johnson said Monday it will acquire Texas-based Ollin Biosciences for $2.2 billion upfront plus up to about $1.13 billion in milestone payments, adding the Phase 3 eye drug OLN324, with closing expected before the end of 2026.

2 min read

Johnson & Johnson said on Monday, November 16, that it has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately $1.125 billion. Reuters valued the deal at up to $3.33 billion on that basis. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions, according to the Johnson & Johnson press release announcing the agreement, covered on the Corporate America desk.

Ollin is a clinical-stage biopharmaceutical company developing therapies for serious eye diseases. Reuters reported that the Texas-based company was established in 2023 and is backed by investment firms ARCH Venture Partners and Mubadala Capital. Johnson & Johnson is headquartered in New Brunswick, New Jersey, and said the acquisition would strengthen its presence in ophthalmology, an area where Reuters noted it has a limited footprint despite its large contact lens business.

The deal centers on OLN324, an investigational bispecific antibody in Phase 3 development. Johnson & Johnson said OLN324 is designed to target two key pathways in retinal diseases, vascular endothelial growth factor and angiopoietin-2, in a small protein format that could enable improved control of retinal fluid. It is being developed for wet age-related macular degeneration and diabetic macular edema, which the company said together affect more than 40 million people worldwide and are leading causes of vision loss. Kip Connor, the company’s ophthalmology disease area leader, said the data generated to date point to a potentially transformative profile that could allow more time between treatments.

Alongside the acquisition, Johnson & Johnson will enter into a separate development funding agreement with Blackstone Life Sciences to support the Phase 3 advancement of OLN324, contingent on the acquisition closing. Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund that Phase 3 development, and in return will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties.

The structure is a reminder that a deal’s headline figure depends on what is counted as paid today and what depends on future milestones, a distinction our explainer on market capitalization versus enterprise value sets out for reading acquisition values. Johnson & Johnson said the accounting treatment for the transaction will be communicated on or before the close, and that the agreement builds on its long-standing work in vision as it seeks to preserve, restore and enhance vision for patients.

Educational coverage — not tax or investment advice.

The Global Close, in your inbox

Markets, briefed. What moved, why it matters, and what to watch next — every weekday morning. Free.

See Market Briefer first in Google

Add to Preferred Sources
Financial disclaimer: This article is for information and education only. It is not investment, legal, tax or accounting advice and does not recommend any transaction. Market data is delayed by approximately 15 minutes.